Abbott Laboratories (ABT)
Abbott Laboratories, discovers, develops, manufactures, and sells health care products worldwide.
Scored against other Healthcare stocks, not a fixed scale.
The quick read
Abbott Laboratories reads as neutral right now, with no clear lean either way.
- What's working
- Nothing stands out as a clear strength right now.
- Worth watching
- No major weak spots stand out in the data right now.
Analyst price target
~12-month · 26 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices…
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 122,000
- Headquarters
- Abbott Park, IL
Similar stocks
What’s behind the score
Valuation
P/E 33.8 — lower than 50% of Healthcare peers
P/B 3.6 — lower than 50% of Healthcare peers
P/S 3.9 — lower than 53% of Healthcare peers
EV/EBITDA 17.9 — lower than 33% of Healthcare peers
EV/Revenue 4.5 — lower than 53% of Healthcare peers
PEG 1.9 — lower than 37% of Healthcare peers
FCF yield 4.0% — higher than 62% of Healthcare peers
Profitability & quality
Gross margin 56.8% — higher than 40% of Healthcare peers
Operating margin 14.7% — higher than 27% of Healthcare peers
Net margin 11.6% — higher than 50% of Healthcare peers
ROE 10.6% — higher than 44% of Healthcare peers
ROA 5.3% — higher than 45% of Healthcare peers
Free cash flow is 133% of reported net income
Financial health
Debt/equity 0.6 — lower than 56% of Healthcare peers
Current ratio 1.38 — higher than 48% of Healthcare peers
Quick ratio 0.80 — higher than 41% of Healthcare peers
Cash/debt 0.17 — higher than 38% of Healthcare peers
Debt/EBITDA 2.80 — lower than 28% of Healthcare peers
Growth
Revenue growth 13.0% YoY — higher than 77% of Healthcare peers
Earnings growth -47.5% YoY — higher than 12% of Healthcare peers
Ownership & investor activity
Payout ratio 78.7% — atypical vs Healthcare peers
Net insider buying, +0.4% of insider shares
Institutions net sold, -14.8% of shares held
Insiders hold 0.5% of shares outstanding
0.9% of float sold short
Momentum
Mixed vs its moving averages
46% of the way from its 52-week low to high